中华胰腺病杂志
中華胰腺病雜誌
중화이선병잡지
CHINESE JOURNAL OF PANCREATOLOGY
2014年
6期
392-395
,共4页
胰腺肿瘤%基因表达%Musashi 2%病理学,临床%预后
胰腺腫瘤%基因錶達%Musashi 2%病理學,臨床%預後
이선종류%기인표체%Musashi 2%병이학,림상%예후
Pancreatic neoplasms%Gene expression%Musashi 2%Pathology,clinical%Prognosis2
目的 检测胰腺导管腺癌(PDAC)组织中Musashi 2(MSI2)蛋白和mRNA的表达,分析癌组织MSI2表达与临床病理参数的相关性.方法 应用免疫组化方法检测61例PDAC组织及配对癌旁组织MSI2蛋白表达水平,采用蛋白质印迹法及实时PCR法检测10例癌组织及配对癌旁组织MSI2蛋白及mRNA的表达.分析癌组织MSI2表达与肿瘤临床病理参数的关系.结果 61例PADC患者癌组织MSI2高表达率为63.9％,配对癌旁组织为41.0％,癌组织的表达显著高于配对的癌旁组织,差异有统计学意义(t =2.809,P=0.007).10例癌组织及癌旁组织的MSI2蛋白表达量分别为0.748±0.195、0.420±0.171;癌组织MSI2 mRNA的表达量为癌旁组织表达量的(2.507±2.981)倍,差异均有统计学意义(t=3.689,P=0.005;t=2.660,P=0.026).癌组织MSI2表达仅与肿瘤大小呈正相关(x2=5.096,P =0.024),而与其他参数均无相关性.MSI2高表达患者的术后中位生存期为321 d,低表达者为730 d,高表达者的生存期显著短于低表达者,差异有统计学意义(x2=6.706,P=0.010).结论 胰腺癌组织中MSI2表达上调,其表达量与肿瘤大小相关,高表达患者的预后差.
目的 檢測胰腺導管腺癌(PDAC)組織中Musashi 2(MSI2)蛋白和mRNA的錶達,分析癌組織MSI2錶達與臨床病理參數的相關性.方法 應用免疫組化方法檢測61例PDAC組織及配對癌徬組織MSI2蛋白錶達水平,採用蛋白質印跡法及實時PCR法檢測10例癌組織及配對癌徬組織MSI2蛋白及mRNA的錶達.分析癌組織MSI2錶達與腫瘤臨床病理參數的關繫.結果 61例PADC患者癌組織MSI2高錶達率為63.9％,配對癌徬組織為41.0％,癌組織的錶達顯著高于配對的癌徬組織,差異有統計學意義(t =2.809,P=0.007).10例癌組織及癌徬組織的MSI2蛋白錶達量分彆為0.748±0.195、0.420±0.171;癌組織MSI2 mRNA的錶達量為癌徬組織錶達量的(2.507±2.981)倍,差異均有統計學意義(t=3.689,P=0.005;t=2.660,P=0.026).癌組織MSI2錶達僅與腫瘤大小呈正相關(x2=5.096,P =0.024),而與其他參數均無相關性.MSI2高錶達患者的術後中位生存期為321 d,低錶達者為730 d,高錶達者的生存期顯著短于低錶達者,差異有統計學意義(x2=6.706,P=0.010).結論 胰腺癌組織中MSI2錶達上調,其錶達量與腫瘤大小相關,高錶達患者的預後差.
목적 검측이선도관선암(PDAC)조직중Musashi 2(MSI2)단백화mRNA적표체,분석암조직MSI2표체여림상병리삼수적상관성.방법 응용면역조화방법검측61례PDAC조직급배대암방조직MSI2단백표체수평,채용단백질인적법급실시PCR법검측10례암조직급배대암방조직MSI2단백급mRNA적표체.분석암조직MSI2표체여종류림상병리삼수적관계.결과 61례PADC환자암조직MSI2고표체솔위63.9％,배대암방조직위41.0％,암조직적표체현저고우배대적암방조직,차이유통계학의의(t =2.809,P=0.007).10례암조직급암방조직적MSI2단백표체량분별위0.748±0.195、0.420±0.171;암조직MSI2 mRNA적표체량위암방조직표체량적(2.507±2.981)배,차이균유통계학의의(t=3.689,P=0.005;t=2.660,P=0.026).암조직MSI2표체부여종류대소정정상관(x2=5.096,P =0.024),이여기타삼수균무상관성.MSI2고표체환자적술후중위생존기위321 d,저표체자위730 d,고표체자적생존기현저단우저표체자,차이유통계학의의(x2=6.706,P=0.010).결론 이선암조직중MSI2표체상조,기표체량여종류대소상관,고표체환자적예후차.
Objective To detect the expression of MSI2 protein and mRNA in pancreatic ductal adenocarcinoma (PDAC) tissue,and investigate the correlation between the expression of MSI2 protein and the clinicopathological parameters.Methods The expression of MSI2 protein in 61 PDAC specimens and paired adjacent non-cancerous pancreatic tissues were detected by immunohistochemistry.Western blot and quantitative real-time PCR (QRT-PCR) were used to examine the expression of MSI2 protein and mRNA level in 10 PDAC specimens and adjacent non-cancerous pancreatic tissues.Then the relationship between MSI2 expression in cancerous tissues and clinicopathological parameters was analyzed.Results In 61 patients with PDAC,the expression rate of MSI2 protein was higher in cancerous tissues (63.9％) compared with that in paired non-cancerous pancreatic tissues (41.0％),and the difference between the two groups was statistically significant (t =2.809,P =0.007).The expression levels of MSI2 protein in 10 fresh PDAC specimens and adjacent non-cancerous pancreatic tissues were 0.748 ± 0.195 and 0.420 ± 0.171,and the expression level of MSI2 mRNA in PDAC specimens was as 2.507 ± 2.981 times as much of adjacent non-cancerous pancreatic tissues,and the difference between the two groups was statistically significant (t =3.689,P=0.005;t =2.660,P =0.026).The expression of MSI2 in cancerous tissues was only positively associated with the size of the tumor (x2 =5.096,P =0.024),but it was not associated with other parameters.The median survival of patients with high MSI2 expression was 321 d,and it was 730 d for patients with low MSI2 expression,and the median survival of patients with high MSI2 expression was significantly shorter than that of low MSI2 expression (x2 =6.706,P =0.010).Conclusions The expression MSI2 is up-regulated in PDAC and related to the tumor size.The patients with high expression of MSI2 protein have poor prognosis.
